Prazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630]. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624].
This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents [FDA label]. Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD)[A176630].
Adrenergic alpha-1 Receptor Antagonists
Alpha-Adrenoreceptor Antagonists and Diuretics
Antiadrenergic Agents, Peripherally Acting
Antihypertensive Agents Indicated for Hypertension
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682